AbbVie Completes Acquisition of Cerevel Therapeutics

Provided By PR Newswire

Last update: Aug 1, 2024

NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of the acquisition, Cerevel is now part of AbbVie.